Test Catalog

CD34+/CD133+ Expression

Clinical information

Diagnostic Utility:

Test that quantifies

  • cells positive for the CD34 membrane receptor (surface antigen of hematopoietic stem cells)
  • cells positive for the CD133 membrane receptor (found in hematopoietic stem cells and endothelial cells)

and determines cellular viability.

It is a determination used as a quality control of products from positive selections of CD133 cells for the treatment of diseases such as Asherman's Syndrome or by IPS cells.

Method

Flow cytometry

Reference Values

The results are quantitative. CD34 and CD133 concentrations can vary greatly depending on the type of sample/product.

Diagnostic Algorithm:

Not applicable.

Response Time:

1 day.

Specimen information

Sample: Peripheral blood, umbilical cord blood, bone marrow, apheresis. 
Tube: EDTA K3 tube (peripheral blood) or Additive-free tube (anticoagulated samples).
Minimum volume: 100 µL
 

Stability:

  • At room temperature: 1 day
  • In refrigeration: 1 day
  • Cryopreserved between -156oC and -196oC: 20 years

Transport instructions: Room temperature

Reason for rejection: Sample with DNA or precipitates

Administrative information

BST Code: CEL017
Test Description: CD34+/CD133+ expression
Synonyms: CD133+
Section: Cellular Laboratory
BST Fee: Check the updated fees here.

Profiles: This test must always be requested together with test CEL007. It is also carried out within the following profiles:

Profile Name Profile Code
INITIAL SEL. CD133 CE33
POSTNIGHT SEL. CD133 CE34
FR SEL. CD133+ CE35
FR SEL. CD133- CE36

References

Cervelló et al. Human CD133Dbonemarrow-derived stem cells promoteendometrial proliferation in a murinemodel of Asherman syndrome; Fertility and Sterility, Volume 104, Issue 6, December 2015, Pages 1552-1560.e3

Santamaria X, et al. Autologous cell therapy with CD1331bone marrow-derived stem cells forrefractory Asherman's syndrome andendometrial atrophy: a pilot cohortstudy; Human Reproduction, Vol.31, No.5 pp. 1087-1096, 2016